Clinical Trial Update: ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse [Phase 2]

View source ↗

Summary

Completed Phase 2 trial evaluating Gefitinib (ZD 1839) for glioblastoma multiforme at first relapse.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Duke University | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED